Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright

Cardiol Therapeutics (NASDAQ:CRDL)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $9.00 price objective on the stock.

Other equities analysts also recently issued research reports about the stock. Rodman & Renshaw started coverage on shares of Cardiol Therapeutics in a research note on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price on the stock. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $8.40.

Cardiol Therapeutics Stock Down 5.1 %

Shares of CRDL opened at $1.11 on Monday. The firm has a market cap of $91.70 million, a PE ratio of -2.85 and a beta of 0.91. The company’s fifty day moving average is $1.31 and its two-hundred day moving average is $1.68. Cardiol Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $3.12. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of CRDL. Wealth Enhancement Advisory Services LLC acquired a new position in Cardiol Therapeutics during the 3rd quarter valued at about $27,000. Townsquare Capital LLC acquired a new position in Cardiol Therapeutics during the 3rd quarter valued at about $27,000. Jane Street Group LLC acquired a new position in Cardiol Therapeutics during the 3rd quarter valued at about $29,000. Lion Street Advisors LLC boosted its stake in Cardiol Therapeutics by 12.6% during the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock valued at $396,000 after purchasing an additional 34,385 shares during the period. Finally, Jones Financial Companies Lllp acquired a new position in Cardiol Therapeutics during the 4th quarter valued at about $25,000. 12.49% of the stock is owned by institutional investors and hedge funds.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.